Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
← catalyst calendarNCT00271180 · readout ≤ 5,247 d
Sponsored by Medtronic (industry) · MDT — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
20,000estimated
Sites
320
Countries
Australia, Austria, Belgium +32
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 1983 | actual | When the study began enrolling |
| Primary completion | Dec 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2005-12-30 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Arrhythmia
- Bradycardia
- Heart Failure
- Sinus Tachycardia
Intervention
- Device: Device
Primary outcome
what the primary-completion date above is the date OFLead related complications for each lead model.
measured Ongoing: Implant to the cardiac lead is terminated from the study if the patient exit, patient death, or out-of-service (e.g. deactivated/inactive).
Permalink · MDT's whole pipeline · Catalyst calendar · Every registered study · What changed